Beam Therapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Beam Therapeutics Debt-to-Equity Ratio Growth & History (BEAM)
Beam Therapeutics's debt-to-equity ratio was 0.12 for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.12 | −0.10 | −43.44% |
| 2024 | 2024-12-31 | 0.22 | 0.04 | +25.05% |
| 2023 | 2023-12-31 | 0.18 | −0.07 | −29.09% |
| 2022 | 2022-12-31 | 0.25 | 0.07 | +38.95% |
| 2021 | 2021-12-31 | 0.18 | −0.26 | −59.26% |
| 2020 | 2020-12-31 | 0.44 | — | — |
Beam Therapeutics quarterly debt-to-equity ratio
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.23 | 0.08 | +57.67% |
| Q1 2026 | 2026-03-31 | 0.22 | 0.08 | +53.86% |
| Q4 2025 | 2025-12-31 | 0.12 | −0.10 | −43.44% |
| Q3 2025 | 2025-09-30 | 0.16 | −0.05 | −23.46% |
| Q2 2025 | 2025-06-30 | 0.15 | −0.05 | −24.03% |
| Q1 2025 | 2025-03-31 | 0.14 | −0.04 | −23.93% |
| Q4 2024 | 2024-12-31 | 0.22 | 0.04 | +25.05% |
| Q3 2024 | 2024-09-30 | 0.20 | −0.02 | −8.30% |
| Q2 2024 | 2024-06-30 | 0.19 | −0.02 | −11.35% |
| Q1 2024 | 2024-03-31 | 0.18 | −0.05 | −21.64% |
| Q4 2023 | 2023-12-31 | 0.18 | −0.07 | −29.09% |
| Q3 2023 | 2023-09-30 | 0.22 | −0.03 | −10.60% |
| Q2 2023 | 2023-06-30 | 0.22 | −0.00 | −1.72% |
| Q1 2023 | 2023-03-31 | 0.23 | 0.05 | +29.70% |
| Q4 2022 | 2022-12-31 | 0.25 | 0.07 | +38.95% |
| Q3 2022 | 2022-09-30 | 0.25 | 0.08 | +46.66% |
| Q2 2022 | 2022-06-30 | 0.22 | −0.04 | −14.61% |
| Q1 2022 | 2022-03-31 | 0.18 | −0.14 | −44.00% |
| Q4 2021 | 2021-12-31 | 0.18 | −0.26 | −59.26% |
| Q3 2021 | 2021-09-30 | 0.17 | −0.00 | −0.73% |
| Q2 2021 | 2021-06-30 | 0.26 | 0.10 | +65.85% |
| Q1 2021 | 2021-03-31 | 0.32 | 0.19 | +136.42% |
| Q4 2020 | 2020-12-31 | 0.44 | — | — |
| Q3 2020 | 2020-09-30 | 0.17 | — | — |
| Q2 2020 | 2020-06-30 | 0.16 | — | — |
| Q1 2020 | 2020-03-31 | 0.14 | — | — |
Beam Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Beam Therapeutics's debt-to-equity ratio decreased from 0.44 to 0.12, a change of −0.31. The latest reported quarter, Q2 2026, shows 0.23.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...